Skip navigation

Calls to Action

Arbaclofen’s Promise and Heartbreak

Families dismayed at cancellation of trials for promising autism medicine; Autism Speaks remains involved in determining effectiveness
June 07, 2013

The experimental autism medicine arbaclofen is making headlines, including today’s feature story in the New York Times. Overall, the medicine failed to show a clear benefit over dummy treatment (placebo) in the largest clinical trial to date. Yet many families reported that it dramatically helped their loved ones with autism. This is a heartbreaking situation for many of those who will now lose access to this experimental treatment.

Autism Speaks wants our community to know that we remain actively involved in guiding further research that can better determine whether arbaclofen is safe and effective. Please check our website for further updates and information in the days, weeks and months ahead.